MedPath

Clinical Trial News

India's Complex Regulatory Landscape Poses Major Hurdles for Pharmaceutical Approvals

  • India's fragmented regulatory system, split between Central and State bodies, creates significant challenges for pharmaceutical companies seeking drug approvals and consistent oversight.
  • Critical shortage of skilled regulatory personnel and trained inspectors hampers effective monitoring and compliance of drug quality standards across the country.
  • Pharmaceutical companies face multiple regulatory challenges including delayed new drug approvals, inadequate data protection, and slow clinical trial authorization processes.

GIP Reduces Free Fatty Acids via 11β-HSD1 Inhibition in Adipose Tissue

  • Glucose-dependent insulinotropic polypeptide (GIP) reduces free fatty acid (FFA) release from adipose tissue by inhibiting lipolysis.
  • GIP's effects are mediated through the modification of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity in adipocytes.
  • Clinical trials show GIP lowers circulating FFAs in obese men and reduces 11β-HSD1 expression and activity in adipose tissue.
  • These findings suggest GIP's role in fine-tuning postprandial metabolism via acute suppression of fat-specific 11β-HSD1 activity.

Obinutuzumab Shows Promise in Treating Proliferative Lupus Nephritis

  • Obinutuzumab, combined with mycophenolate and corticosteroids, significantly improved complete renal response (CRR) rates in patients with proliferative lupus nephritis (LN) at week 104.
  • The study demonstrated that obinutuzumab led to greater improvements in anti-dsDNA antibodies, complement levels (C3, C4), estimated glomerular filtration rate (eGFR), and proteinuria compared to placebo.
  • Obinutuzumab facilitated rapid and sustained depletion of peripheral CD19+ B cells without increasing serious adverse events, serious infections, or deaths.
  • The treatment effect of obinutuzumab was most pronounced in patients with high baseline proteinuria and those with Class IV lupus nephritis.

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis

NCT04221477Active, Not RecruitingPhase 3
Hoffmann-La Roche
Posted 8/10/2020

Barriers to Personalized Medicine: Payer Reimbursement Challenges Slow Diagnostic Test Adoption

  • Less than 5% of US private companies currently reimburse for genetic tests, creating a significant barrier to personalized medicine adoption despite its potential to reduce healthcare costs.
  • Studies show personalized medicine diagnostic tests can generate savings between $600-$28,000 per patient, with successful examples like Oncotype DX demonstrating $1,930 savings per patient through reduced chemotherapy needs.
  • Pay-for-performance models are emerging as a potential solution, growing at 26% annually in the US, offering a win-win approach for pharmaceutical companies and payers in personalized medicine implementation.

Advancements in CAR-Modified T Cells for Leukemia Treatment

Recent developments in cellular immunotherapy have introduced CAR-modified T cells targeting the CD19 antigen as a promising strategy for treating B-cell cancers. Despite challenges in clinical trial design and CAR structure, early trials show potential for significant impact on disease progression.

CD19 Chimeric Receptor Expressing T Lymphocytes in B-Cell Non Hodgkin's Lymphoma, ALL & CLL

NCT00586391Active, Not RecruitingPhase 1
Baylor College of Medicine
Posted 2/1/2009

Allo CART-19 Protocol

NCT01551043TerminatedPhase 1
University of Pennsylvania
Posted 9/1/2010

Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

NCT01593696CompletedPhase 1
National Cancer Institute (NCI)
Posted 6/29/2012

Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT

NCT00840853Active, Not RecruitingPhase 1
Baylor College of Medicine
Posted 4/1/2009

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

NCT01475058CompletedPhase 1
Fred Hutchinson Cancer Center
Posted 4/1/2012

Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

NCT00995137CompletedPhase 1
St. Jude Children's Research Hospital
Posted 10/1/2009

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT01044069Active, Not RecruitingPhase 1
Memorial Sloan Kettering Cancer Center
Posted 1/5/2010

CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma

NCT00924326CompletedPhase 1
National Cancer Institute (NCI)
Posted 2/17/2009

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

NCT00466531Active, Not RecruitingPhase 1
Memorial Sloan Kettering Cancer Center
Posted 3/21/2007

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

NCT01416974CompletedPhase 1
Memorial Sloan Kettering Cancer Center
Posted 8/22/2011

CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy

NCT01029366CompletedPhase 1
University of Pennsylvania
Posted 3/17/2010

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

NCT00968760CompletedPhase 1
M.D. Anderson Cancer Center
Posted 6/20/2011

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

NCT01430390Active, Not RecruitingPhase 1
Memorial Sloan Kettering Cancer Center
Posted 9/1/2011

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

NCT01497184CompletedPhase 1
M.D. Anderson Cancer Center
Posted 12/1/2011

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

NCT01087294CompletedPhase 1
National Cancer Institute (NCI)
Posted 8/4/2010

FDA Approves Xarelto for Atrial Fibrillation Treatment

  • The FDA has approved Xarelto (rivaroxaban) for treating atrial fibrillation, a common heart disorder increasing stroke risk.
  • Xarelto, developed by Johnson & Johnson and Bayer, is a once-daily pill already approved for preventing strokes post-hip and knee replacements.
  • The drug's approval offers a new treatment option for afib patients, who have primarily relied on warfarin, a difficult-to-manage blood thinner.
  • Xarelto functions by blocking clotting protein factor Xa and carries a boxed warning about stroke risk if discontinued without physician advice.

Lifestyle and Metformin Interventions Show Significant Benefits in Diabetes Prevention

A comprehensive analysis of the Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) reveals that lifestyle changes and metformin significantly reduce the risk of developing diabetes. Adherent participants to these interventions experienced a lower incidence of diabetes and accrued more quality-adjusted life-years (QALYs) compared to those on placebo. The study also highlights the cost-effectiveness of these interventions from a health system perspective, with lifestyle and metformin interventions being cost-saving relative to placebo.

Four Key Drivers Reshaping Successful Oncology Drug Launches in Modern Market

  • The oncology market is experiencing significant transformation, with growth rates slowing despite remaining the top therapy area, requiring new strategic approaches for successful drug launches.
  • Companies must focus on optimal indication sequencing, patient segmentation through biomarkers, and novel payer acceptance strategies to navigate increasingly restrictive market access.
  • Building a strong oncology franchise through long-term commitment, engagement with key opinion leaders, and strategic clinical trial planning is crucial for commercial success.

FDA Approves Lialda for Maintenance of Remission in Ulcerative Colitis Patients

The U.S. Food and Drug Administration (FDA) has approved Shire plc's Lialda (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis, following a six-month study demonstrating its safety and effectiveness. This approval adds to Lialda's previous indication for inducing remission in patients with active, mild to moderate ulcerative colitis.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.